KR102492433B1 - 조작된 면역글로불린 람다 경쇄 유전자좌를 갖는 비인간 동물 - Google Patents

조작된 면역글로불린 람다 경쇄 유전자좌를 갖는 비인간 동물 Download PDF

Info

Publication number
KR102492433B1
KR102492433B1 KR1020217034468A KR20217034468A KR102492433B1 KR 102492433 B1 KR102492433 B1 KR 102492433B1 KR 1020217034468 A KR1020217034468 A KR 1020217034468A KR 20217034468 A KR20217034468 A KR 20217034468A KR 102492433 B1 KR102492433 B1 KR 102492433B1
Authority
KR
South Korea
Prior art keywords
human
light chain
mouse
gene segments
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217034468A
Other languages
English (en)
Korean (ko)
Other versions
KR20210134059A (ko
Inventor
춘광 궈
페이쓰 해리스
베라 보로니나
존 맥훠터
나타샤 레벤코바
린 맥도날드
낙신 투
앤드류 제이. 머피
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Priority to KR1020237002504A priority Critical patent/KR102658529B1/ko
Publication of KR20210134059A publication Critical patent/KR20210134059A/ko
Application granted granted Critical
Publication of KR102492433B1 publication Critical patent/KR102492433B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217034468A 2016-11-04 2017-11-03 조작된 면역글로불린 람다 경쇄 유전자좌를 갖는 비인간 동물 Active KR102492433B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237002504A KR102658529B1 (ko) 2016-11-04 2017-11-03 조작된 면역글로불린 람다 경쇄 유전자좌를 갖는 비인간 동물

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662417845P 2016-11-04 2016-11-04
US62/417,845 2016-11-04
US201762567932P 2017-10-04 2017-10-04
US62/567,932 2017-10-04
PCT/US2017/060006 WO2018128691A1 (en) 2016-11-04 2017-11-03 Non-human animals having an engineered immunoglobulin lambda light chain locus
KR1020197015717A KR102319069B1 (ko) 2016-11-04 2017-11-03 조작된 면역글로불린 람다 경쇄 유전자좌를 갖는 비인간 동물

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197015717A Division KR102319069B1 (ko) 2016-11-04 2017-11-03 조작된 면역글로불린 람다 경쇄 유전자좌를 갖는 비인간 동물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237002504A Division KR102658529B1 (ko) 2016-11-04 2017-11-03 조작된 면역글로불린 람다 경쇄 유전자좌를 갖는 비인간 동물

Publications (2)

Publication Number Publication Date
KR20210134059A KR20210134059A (ko) 2021-11-08
KR102492433B1 true KR102492433B1 (ko) 2023-01-30

Family

ID=62025924

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020217034468A Active KR102492433B1 (ko) 2016-11-04 2017-11-03 조작된 면역글로불린 람다 경쇄 유전자좌를 갖는 비인간 동물
KR1020237002504A Active KR102658529B1 (ko) 2016-11-04 2017-11-03 조작된 면역글로불린 람다 경쇄 유전자좌를 갖는 비인간 동물
KR1020247012338A Pending KR20240055863A (ko) 2016-11-04 2017-11-03 조작된 면역글로불린 람다 경쇄 유전자좌를 갖는 비인간 동물
KR1020197015717A Active KR102319069B1 (ko) 2016-11-04 2017-11-03 조작된 면역글로불린 람다 경쇄 유전자좌를 갖는 비인간 동물

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020237002504A Active KR102658529B1 (ko) 2016-11-04 2017-11-03 조작된 면역글로불린 람다 경쇄 유전자좌를 갖는 비인간 동물
KR1020247012338A Pending KR20240055863A (ko) 2016-11-04 2017-11-03 조작된 면역글로불린 람다 경쇄 유전자좌를 갖는 비인간 동물
KR1020197015717A Active KR102319069B1 (ko) 2016-11-04 2017-11-03 조작된 면역글로불린 람다 경쇄 유전자좌를 갖는 비인간 동물

Country Status (26)

Country Link
US (3) US10820582B2 (https=)
EP (4) EP4082334B1 (https=)
JP (5) JP6884860B2 (https=)
KR (4) KR102492433B1 (https=)
CN (2) CN109996441B (https=)
AU (2) AU2017391167B2 (https=)
BR (1) BR112019008675A2 (https=)
CA (1) CA3038720A1 (https=)
CY (2) CY1123491T1 (https=)
DK (3) DK4082334T3 (https=)
ES (3) ES2915609T3 (https=)
FI (1) FI4082334T3 (https=)
HR (3) HRP20201403T1 (https=)
HU (3) HUE052087T2 (https=)
IL (2) IL266282B2 (https=)
LT (3) LT4082334T (https=)
MA (2) MA53935A (https=)
MX (2) MX385857B (https=)
PL (3) PL4082334T3 (https=)
PT (3) PT3766343T (https=)
RS (3) RS63390B1 (https=)
RU (2) RU2757665C2 (https=)
SG (2) SG10201913483XA (https=)
SI (3) SI4082334T1 (https=)
SM (3) SMT202500204T1 (https=)
WO (1) WO2018128691A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6482757B2 (ja) 2010-07-26 2019-03-13 トリアンニ インコーポレイテッドＴｒｉａｎｎｉ，Ｉｎｃ． トランスジェニック動物および使用方法
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
RS62023B1 (sr) * 2012-02-01 2021-07-30 Regeneron Pharma Humanizovani glodari koji eksprimiraju teške lance koji sadrže vl domene
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
WO2018128691A1 (en) 2016-11-04 2018-07-12 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus
WO2019190922A1 (en) 2018-03-24 2019-10-03 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
KR20250121150A (ko) 2018-03-26 2025-08-11 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
JP2022520819A (ja) 2019-02-22 2022-04-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 遺伝子改変ナトリウムチャネルを有する齧歯類およびその使用方法
WO2021003152A1 (en) * 2019-07-01 2021-01-07 Trianni, Inc. Transgenic mammals and methods of use thereof
KR20230018439A (ko) * 2020-06-02 2023-02-07 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물
CA3187680A1 (en) 2020-09-11 2022-03-17 Yashu Liu Identification and production of antigen-specific antibodies
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
TW202242114A (zh) 2020-12-23 2022-11-01 美商再生元醫藥公司 用於獲得結合至跨膜蛋白之抗體以及抗體生成細胞的方法
IL312359A (en) * 2021-11-10 2024-06-01 Trianni Inc Transgenic mammals and methods of use thereof
GB202217978D0 (en) * 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026035843A2 (en) 2024-08-06 2026-02-12 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011163311A1 (en) 2010-06-22 2011-12-29 Regeneron Pharmaceuticals, Inc. Mice expressing alight chain with human lambda variable and mouse constant regions
WO2013096142A1 (en) 2011-12-20 2013-06-27 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
US20140283150A1 (en) 2013-03-18 2014-09-18 Kymab Limited Animal Models and Therapeutic Molecules
JP2015512634A (ja) 2012-03-28 2015-04-30 カイマブ・リミテッド 動物モデルおよび治療用分子

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2124967C (en) * 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7435871B2 (en) 2001-11-30 2008-10-14 Amgen Fremont Inc. Transgenic animals bearing human Igλ light chain genes
EP1644417B1 (en) * 2003-07-15 2014-04-30 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
EP2346994B1 (en) 2008-09-30 2022-02-16 Ablexis, LLC Knock-in mice for the production of chimeric antibodies
JP5827127B2 (ja) * 2008-12-18 2015-12-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用
BR112012000536A2 (pt) 2009-07-08 2020-08-11 Kymab Limited métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
WO2011115476A1 (en) 2010-03-17 2011-09-22 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes later in life
RU2722373C2 (ru) 2011-02-25 2020-05-29 Редженерон Фармасьютикалс, Инк. Мыши adam6
KR20160098514A (ko) 2011-10-17 2016-08-18 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
EP2840892B1 (en) * 2013-02-20 2018-04-18 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
MX2015010841A (es) 2013-02-20 2016-05-09 Regeneron Pharma Modificacion genetica de ratas.
DE112014004537T5 (de) * 2013-10-01 2016-07-21 Kymab Limited Tiermodelle und therapeutische Moleküle
US9546384B2 (en) 2013-12-11 2017-01-17 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a mouse genome
RS60359B1 (sr) 2014-06-06 2020-07-31 Regeneron Pharma Postupci i kompozicije za modifikovanje ciljanog lokusa
HUE049405T2 (hu) 2014-06-23 2020-09-28 Regeneron Pharma Nukleáz-közvetített DNS-összeállítás
ES2731437T3 (es) 2014-11-21 2019-11-15 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías
KR102530821B1 (ko) 2014-12-19 2023-05-10 리제너론 파마슈티칼스 인코포레이티드 단일 단계 다중 표적화를 통한 표적화된 유전자 변형을 위한 방법 및 조성물
WO2018128691A1 (en) 2016-11-04 2018-07-12 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011163311A1 (en) 2010-06-22 2011-12-29 Regeneron Pharmaceuticals, Inc. Mice expressing alight chain with human lambda variable and mouse constant regions
WO2013096142A1 (en) 2011-12-20 2013-06-27 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
JP2015512634A (ja) 2012-03-28 2015-04-30 カイマブ・リミテッド 動物モデルおよび治療用分子
US20140283150A1 (en) 2013-03-18 2014-09-18 Kymab Limited Animal Models and Therapeutic Molecules

Also Published As

Publication number Publication date
US12433264B2 (en) 2025-10-07
PL3407709T3 (pl) 2021-01-11
MX385857B (es) 2025-03-18
ES2823305T3 (es) 2021-05-06
RU2021129958A (ru) 2021-11-02
EP4082334A1 (en) 2022-11-02
CN114369157A (zh) 2022-04-19
NZ753456A (en) 2021-08-27
SI4082334T1 (sl) 2025-06-30
HRP20220888T1 (hr) 2022-10-28
RS66884B1 (sr) 2025-07-31
RU2757665C2 (ru) 2021-10-20
IL266282A (en) 2019-06-30
EP4567119A3 (en) 2025-09-24
EP4567119A2 (en) 2025-06-11
MX2021010556A (es) 2021-10-01
IL266282B2 (en) 2024-04-01
CN109996441B (zh) 2022-02-08
US10820582B2 (en) 2020-11-03
RS63390B1 (sr) 2022-08-31
WO2018128691A8 (en) 2019-02-28
JP6884860B2 (ja) 2021-06-09
IL308197A (en) 2024-01-01
MA53935A (fr) 2021-12-22
HRP20201403T1 (hr) 2020-11-27
PL3766343T3 (pl) 2022-09-26
EP3766343B1 (en) 2022-05-11
CN109996441A (zh) 2019-07-09
KR102658529B1 (ko) 2024-04-19
US20180125043A1 (en) 2018-05-10
SG10201913483XA (en) 2020-03-30
PL4082334T3 (pl) 2025-08-11
US20210029978A1 (en) 2021-02-04
ES3035365T3 (en) 2025-09-02
KR20210134059A (ko) 2021-11-08
SG11201903344XA (en) 2019-05-30
SMT202000558T1 (it) 2020-11-10
KR102319069B1 (ko) 2021-11-01
FI4082334T3 (fi) 2025-06-10
AU2017391167A1 (en) 2019-05-30
EP3407709B1 (en) 2020-07-29
HUE071595T2 (hu) 2025-09-28
WO2018128691A1 (en) 2018-07-12
JP7386292B2 (ja) 2023-11-24
HUE052087T2 (hu) 2021-04-28
AU2024200582A1 (en) 2024-03-28
CY1123491T1 (el) 2022-03-24
JP2025166207A (ja) 2025-11-05
EP4082334B1 (en) 2025-03-26
HRP20250695T1 (hr) 2025-08-01
AU2017391167B2 (en) 2024-02-15
JP2023053400A (ja) 2023-04-12
PT3766343T (pt) 2022-05-30
SMT202500204T1 (it) 2025-07-22
PT3407709T (pt) 2020-08-20
ES2915609T3 (es) 2022-06-23
MA44091A (fr) 2018-10-24
KR20240055863A (ko) 2024-04-29
US20260068860A1 (en) 2026-03-12
SI3407709T1 (sl) 2020-10-30
SI3766343T1 (sl) 2022-06-30
JP2022130725A (ja) 2022-09-06
JP2021090455A (ja) 2021-06-17
LT3766343T (lt) 2022-06-10
DK3407709T3 (da) 2020-08-31
EP3766343A1 (en) 2021-01-20
RU2019112589A3 (https=) 2021-03-30
BR112019008675A2 (pt) 2019-07-09
KR20190076024A (ko) 2019-07-01
DK4082334T3 (da) 2025-06-02
RU2019112589A (ru) 2020-12-04
LT4082334T (lt) 2025-05-26
LT3407709T (lt) 2020-10-12
DK3766343T3 (da) 2022-06-20
KR20230020550A (ko) 2023-02-10
EP3407709A1 (en) 2018-12-05
CY1125474T1 (el) 2025-05-09
JP2020501516A (ja) 2020-01-23
PT4082334T (pt) 2025-05-21
AU2024200582B2 (en) 2026-04-09
SMT202200259T1 (it) 2022-07-21
HUE061980T2 (hu) 2023-09-28
EP3407709B9 (en) 2021-10-06
MX2019005256A (es) 2019-08-05
RS60886B1 (sr) 2020-11-30
IL266282B1 (en) 2023-12-01
CA3038720A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
KR102492433B1 (ko) 조작된 면역글로불린 람다 경쇄 유전자좌를 갖는 비인간 동물
KR102760506B1 (ko) 조작된 면역글로불린 람다 경쇄를 갖는 비-인간 동물 및 그의 용도
RU2843837C2 (ru) Отличные от человека животные, имеющие ограниченный репертуар легких лямбда-цепей, экспрессируемый из локуса капли, и их применение
HK40082722B (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
HK40127071A (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
HK40082722A (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
HK40045047B (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
HK40045047A (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
HK40001433A (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
HK40001433B (en) Non-human animals having an engineered immunoglobulin lambda light chain locus

Legal Events

Date Code Title Description
A107 Divisional application of patent
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4